

UNITED STATES DISTRICT COURT  
DISTRICT OF NEW JERSEY

HELSINN HEALTHCARE S.A., et al.,

Plaintiffs,

v.

DR. REDDY'S LABORATORIES, LTD.,  
et al.,

Defendants.

CIVIL ACTION NO. 12-2867 (MLC)

**ORDER**

**PLAINTIFFS**, Helsinn Healthcare S.A. and Roche Palo Alto LLC, and Defendants, Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc., asking the Court to construe the claim term "chelating agent" in United States Patent Number 7,947,724 (see, e.g., dkt. entry no. 69, Joint Claim Construction & Prehearing Statement at 3–4); and the Court having conducted a Markman hearing on October 21, 2014 and December 17, 2014 (see dkt. entry nos. 81, 87); and the Court having considered the parties' submissions (see dkt. entry nos. 73, 74, 76, 77) and argument; and for the reasons stated on the record and in the forthcoming memorandum opinion:

Dr. Reddy's Laboratories, Ltd., et al.  
v.  
Helsinn Healthcare S.A., et al.

**IT IS THEREFORE** on this 19th day of February, 2015, **ORDERED** that the Court construes the term “chelating agent” to mean a “multidentate ligand that can form a ring structure by reacting with a metal ion.” A separate memorandum opinion is to be filed. And it is hereby **SO ORDERED**.

s/ Mary L. Cooper  
**MARY L. COOPER**  
United States District Judge